GC Biopharma [Green Cross Corporation] is a biopharmaceutical company headquartered in Yongin, South Korea. GC Biopharma specializes in the development and commercialization of vaccines, protein therapies, and therapeutic antibodies for use in the fields of oncology and infectious disease. GC Biopharma was established as "Sudo Microorganism Medical Supplies Co." in 1967, and changed the name to "Green Cross" in 1971. The company is engaged in research, development, manufacturing and sales of biotherapeutics, including plasma proteins, recombinant antibodies, and vaccines. Green Cross developed "Hepavax B", the world's third hepatitis B vaccine, in 1983, the world's first vaccine “Hantavax” against epidemic hemorrhagic fever in 1988, the world's second varicella vaccine in 1995, "Greengene", the world's 4th recombinant antihemophilic drug, and the world's second treatment of Hunter syndrome “Hunterase” in 2012. As part of GC Biopharma's global strategies, there are three operations based in the overseas as of 2016. GC China was established in Anhui Province, China and, has produced plasma derivative products. GC China has established a pharmaceutical wholesaler in 2012. Wikipedia